Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables - Other for 6 consecutive years, with $20.0 million as the latest value for Q1 2025.

  • Quarterly Receivables - Other rose 885.22% to $20.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Mar 2025, up 885.22% year-over-year, with the annual reading at $900000.0 for FY2024, 76.32% down from the prior year.
  • Receivables - Other for Q1 2025 was $20.0 million at Kymera Therapeutics, up from $900000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $20.0 million in Q1 2025, with the low at $100000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $3.4 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Receivables - Other tumbled 88.89% in 2021, then skyrocketed 2400.0% in 2022.
  • Over 5 years, Receivables - Other stood at $100000.0 in 2021, then surged by 2400.0% to $2.5 million in 2022, then soared by 52.0% to $3.8 million in 2023, then plummeted by 76.32% to $900000.0 in 2024, then skyrocketed by 2122.22% to $20.0 million in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $20.0 million, $900000.0, and $1.3 million for Q1 2025, Q4 2024, and Q3 2024 respectively.